Employees working at Big Orthos should be more financially literate and read the public disclosures each quarter.
What we are seeing right now in the C-suites of "Big Ortho" isn’t just disappointing—it’s shameful.
The recent disclosures regarding Johnson & Johnson’s executive compensation are a slap in the face to every hard-working employee, every surgeon using their tools, and every patient paying a premium for healthcare.
The Math of Greed
Let’s look at the numbers, because they don’t lie.
In 2023, J&J grew by roughly 6%. In a vacuum, that’s solid. But look at how the spoils were divided:
CEO Joaquin Duato: Received a 35% increase in pay.
The CFO: Got a 14% increase.
The EVP: Received a 25% increase.
The EVP of R&D: A staggering 36% increase. (For what? We certainly aren't seeing a 36% leap in market-disrupting innovation).
Meanwhile, the median employee—the people actually manufacturing the implants, managing the logistics, and supporting the backbone of the company—saw a 10% increase. While 10% sounds okay on paper, let’s talk about the "Disparity Gap."
The Widening Chasm
When you extrapolate double-digit millions for the top brass against single-digit tens of ...
